Wedbush Downgrades Stemline Therapeutics (STML) to Neutral
- Wall Street comes off record highs ahead of big tech earnings
- Tesla (TSLA) Gains on Q2 Beat, Analysts Mostly Positive but Others Cautious
- China's Meituan (MPNGF) Plunges 17.6% to Push Hang Seng Index to 8-Month Lows as Heavy Selling Continues
- Raytheon (RTX) Gains on Beat-and-Raise, CEO Says Next War Will Be Fought in Cyber Space and Then Outer Space
- Dollar eases slightly with Fed in focus
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten downgraded Stemline Therapeutics (NASDAQ: STML) from Outperform to Neutral with a price target of $18.00.
Shares of Stemline Therapeutics closed at $16.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Argus Downgrades AT&T (T) to Hold; Math 'Doesn't Work' on Dividend
- Deutsche Bank Downgrades New Oriental Education & Technology Group (9901:HK) to Hold
- BTIG Downgrades Medallia Inc. (MDLA) to Neutral
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!